On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster

Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.  

Waiting
• Source: Shutterstock

It’s a nail-biting time for UK-based biotech Verona Pharma plc. Over 15 years since its founding, Verona will soon deliver results of a second Phase III trial of chronic obstructive pulmonary disease (COPD) hopeful ensifentrine. If it replicates the strongly positive efficacy and safety data seen in a first study, the company has a blockbuster in its hands, according to analysts. If not, Verona's survival may be at stake.

This binary outlook is typical for an asset-focused biotech. What’s less ordinary about Nasdaq-listed Verona is that it’s gearing up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.